11/08/2025
A new once-daily cystic fibrosis (CF) treatment trialled in Manchester has been approved for NHS use, following a recommendation made earlier this month by the National Institute for Health and Care Excellence (NICE).
Clinical trials delivered at the National Institute for Health and Care Research (NIHR) Manchester Clinical Research Facility (CRF), part of Manchester University NHS Foundation Trust (MFT), have shown the new triple therapy Alyftrek® to be at least as effective as current drug Kaftrio® at improving lung function for people aged over 12 with CF caused by a specific gene (F508del) mutation.
Cystic Fibrosis is a rare genetic condition affecting more than 10,000 people in the UK. It causes thick, sticky mucus to build up in the lungs, digestive system and other organs causing a wide range of challenging symptoms. The condition is caused by reduced quantity and/or function of the CF transmembrane conductance regulator (CFTR) protein that regulates levels of sodium and chloride in cells.
Professor Alex Horsley, Consultant at the Manchester Cystic Fibrosis Centre, was the Lead Investigator. Adam Higson, 45, from Rochdale was diagnosed with CF in 1980, when he was 11-months old. He took part in the clinical trial at the NIHR Manchester CRF at Wythenshawe Hospital.
Read more👇
https://manchestercrf.nihr.ac.uk/latest-news/life-changing-cystic-fibrosis-treatment-trialled-in-manchester-now-approved-for-nhs-use/
